TLDR
- TNGX stock jumped 45% after reporting a 92% objective response rate in pancreatic cancer patients using vopimetostat plus daraxonrasib
- The combo achieved a 100% disease control rate across 12 evaluable patients, with 90% surviving without disease progression at 6 months
- A second combination — vopimetostat plus zoldonrasib — showed a 52% objective response rate in 27 patients
- Both combinations were well-tolerated; no Grade 4 or 5 adverse events, no treatment discontinuations
- Tango plans to move the vopimetostat/daraxonrasib combo into Phase 3 trials for first-line MTAP-deleted pancreatic cancer in H2 2026
Tango Therapeutics (TNGX) stock jumped 45% in premarket trading Monday after the company released early-stage trial data showing its drug combination shrank tumors in nearly all patients with advanced pancreatic cancer.
Tango Therapeutics, Inc., TNGX
The headline number: a 92% objective response rate in patients treated with vopimetostat plus Revolution Medicines’ daraxonrasib. That means 11 of 12 evaluable patients with metastatic pancreatic ductal adenocarcinoma responded to the treatment.
The combination also hit a 100% disease control rate. Nine of 11 responses were confirmed, and 90% of patients had not seen their disease worsen at the 6-month mark.
These are patients with second and third-line metastatic disease — people who had already been through prior treatments. Over 70% had liver metastases.
Median progression-free survival had not yet been reached as of the May 28 data cutoff, which is generally a good sign at this stage of a trial.
Patients in the trial received either vopimetostat 200mg or 250mg once daily, combined with daraxonrasib 100mg once daily. The data was collected from 59 total patients across both pancreatic cancer and non-small cell lung cancer arms.
A Second Combo Also Shows Promise
Tango also reported results from a second drug combination — vopimetostat plus Revolution’s zoldonrasib — in 27 evaluable pancreatic cancer patients.
That arm showed a 52% objective response rate and a 74% 6-month progression-free survival rate. Tumors shrank in 14 of 27 patients.
While not as striking as the daraxonrasib arm, the data adds weight to vopimetostat’s potential across multiple combination partners.
Both combinations were generally well-tolerated. Most adverse events were Grade 1 or 2. The most common side effects in the daraxonrasib combo were rash, stomatitis/mucositis, and diarrhea. No Grade 4 or 5 events were reported, and no patients dropped out due to adverse events.
What Comes Next
Tango plans to advance vopimetostat plus daraxonrasib into Phase 3 development. The target: first-line MTAP-deleted pancreatic cancer patients.
The company expects to finalize the Phase 3 trial design in the second half of 2026, pending discussions with regulators.
MTAP deletions occur in roughly 40% of pancreatic cancers and around 15% of lung cancers — a defined patient population that gives the trial a clear genetic selection criteria.
The data also comes just one week after Revolution Medicines presented daraxonrasib data at ASCO, where the drug was shown to double survival in pancreatic cancer patients.
Tango’s vopimetostat is an oral drug designed specifically to target cancer cells carrying MTAP deletions.
Revolution Medicines (RVMD) stock slipped 4.15% on the day.
🚨 Our MAY Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for May, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
